News
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...
The U.S. Environmental Protection Agency has drafted a plan to eliminate all limits on greenhouse gases from coal and ...
The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ...
The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.
Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy ...
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...
For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...
It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results